| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | -0.17 | 0.0001 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.17 | 0.0003 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0004 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0005 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | -0.19 | 0.0006 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.17 | 0.0006 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0009 |
| mRNA | GW 441756 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0009 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.001 |